Ac-SDKP vs TB-500
Research Verdict
Ac-SDKP is the stronger research reference for the stated comparison criteria. Ac-SDKP has the broader independent evidence base; TB-500 fragment evidence is limited to preclinical repair studies.
Quick Answers
Which is better, Ac-SDKP or TB-500?
Ac-SDKP is the stronger research reference for the stated comparison criteria. Ac-SDKP has the broader independent evidence base; TB-500 fragment evidence is limited to preclinical repair studies.
What is the key difference between Ac-SDKP and TB-500?
Ac-SDKP is an endogenous four-amino-acid anti-fibrotic fragment. TB-500 commonly refers to thymosin beta-4 fragment 17-23, LKKTETQ. Neither is the full 43-amino-acid thymosin beta-4 molecule.
Evidence Comparison
Ac-SDKP has extensive independent anti-fibrotic mechanistic and animal evidence. Direct TB-500 fragment 17-23 evidence is much smaller and includes a positive 2026 rat tendon study. Full-length thymosin beta-4 trials do not establish human efficacy for TB-500.
Evidence Context Favoring Ac-SDKP
Anti-fibrotic research specifically, where the shorter peptide with defined anti-fibrotic mechanism is preferred.
Evidence Context Favoring TB-500
Preclinical tendon-healing research centered on the direct 2026 TB-500 animal study.
Side-by-Side Snapshot
| Evidence grade | Ac-SDKP: Level D TB-500: Level C |
|---|---|
| Research status | Ac-SDKP: Preclinical TB-500: Preclinical |
| Primary category | Ac-SDKP: Healing & Recovery TB-500: Healing & Recovery |
| Cited studies | Ac-SDKP: 3 TB-500: 9 |